Transitional Drugs 7 supplies five medicines losing exclusivity to NWSSP
- NHS Wales Shared Services Partnership
- Wales
- Open procedure, 19 bids
- 1 July 2026 to 30 June 2028
NHS Wales Shared Services Partnership awarded Transitional Drugs 7 for £16.8m, less than a third of its £53.6m estimate.
The contract covers five medicines that have lost, or will soon lose, exclusivity: Eculizumab, Icatibant, Nintedanib, Omalizumab and Tocilizumab. Each product first had to pass a quality check. Bids were then scored 85% on overall cost and 15% on environmental, social and community benefits.
The open tender drew 19 bids. The partnership split the award between 10 suppliers in June 2026, among them Amgen Ltd, Celltrion Healthcare and Roche. The two-year contract runs to June 2028 and can be extended by up to two years.
Contract ends June 2028
- What
- Medicines supply
- Supplier
- 10 suppliers
- Amgen Ltd and 9 more
- Value
- £16.8m
- How it was bought
- Open procedure
- 19 bids
- Dates and next
- Jul 2026 to Jun 2028
- Being re-tendered now